The awarding ceremony of the nominees and winners of the National
award in the field of import substitution "Priority-2015" was held in
the atrium of the Pushkin State Museum of Fine Arts on December 9 in
Moscow. GEROPHARM Group has become a prizewinner in the nomination
"Pharmaceutical industry".
The main objective of the National award "Priority" is to provide
assistance in the active development of import substitution in Russia as
the largest world class goods and services supplier, to raise
credibility towards local manufacturers, to increase demand for local
products and technologies and to attract additional investment for
production modernization and quality improvement of manufacturing
products.
The contest was staged in the nominations corresponding to the main
strategic directions of import substitution, set by the Government of
the Russian Federation. All together there were 16 nominations,
including the following fields: mechanical engineering, agriculture,
chemical industry, high technologies, software, defense industry,
pharmaceutical industry and other significant branches.
Relying on a number of important achievements in the pharmaceutical
industry, GEROPHARM Group, the only Russian manufacturer of genetically
engineered human insulins on the basis of full cycle principle,
participated in the Award. The key element of GEROPHARM Group’s strategy
is the saturation of the Russian market with the available local drug
products of high quality. Having realized some successful projects on
import substitution for the market, the company is actively investing in
technological development and innovative infrastructure.
"I am glad that the achievements of all out team were highly
appreciated," comments Petr Rodionov, the head of GEROPHARM Group. "Our
own production technology of such vital drugs as insulins within the
country is an indispensable condition for medicinal safety and the
safety of all our citizens. Import substitution is not an end in itself,
but one of the means to overcome the country’s vulnerability in
technologies, professional competences and to create and strengthen the
competitive advantages in all spheres. I am also glad that our team has
made a considerable contribution to the development of pharmaceutical
industry in Russia".
Having opened insulin manufacturing plant in the Moscow region in 2013, GEROPHARM Group has managed in two years to increase its substance production capacity and produce drugs in new modern delivery forms and also increase its market share significantly by means of optimized and intensified production processes. The created modern technological platform and the accumulated competences will give the company an opportunity introduce to the market a full pipeline of analogue insulins - lispro, aspart, glargin, degludec in the near future, in 2019.